INOVIO 将参加两场科学会议，展示 DNA 药物与 INO-D001 血友病 A 数据
INOVIO to Participate in Upcoming Scientific Conferences
INOVIO 宣布将参加两场科学会议：11 月 8 日纽约 Soft Bones 第三届低磷酸酯酶症国际科学会议，报告下一代 DNA 药物在罕见病蛋白替代治疗中的潜力；11 月 12 日蒙特利尔世界血友病联盟新技术与基因治疗研讨会，报告血友病 A 项目 INO-D001。
, /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conferences:
Soft Bones Third International Scientific Meeting on Hypophosphatasia (New York)
Presentation: Rare Disease Protein Replacement Therapeutics: The Transformational Potential of Next-Gen DNA Medicine
Date: Sunday, November 8
World Federation of Hemophilia - New Technology & Gene Therapy (NTGT) Workshop (Montreal)
Presentation: INO-D001 for Hemophilia A
Date: Thursday, November 12
Abstracts and presentations will be added to our events page if available.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that enable the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Josephine Galatioto - ICR Healthcare, [email protected]
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, [email protected]
SOURCE INOVIO Pharmaceuticals, Inc.
来源：PR Newswire Health · prnewswire.com